HC Wainwright Has Optimistic Outlook of BioNTech Q2 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Investment analysts at HC Wainwright upped their Q2 2025 EPS estimates for BioNTech in a research report issued on Wednesday, June 25th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of $3.78 per share for the quarter, up from their prior estimate of $3.72. HC Wainwright has a “Buy” rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share.

Several other research firms have also recently commented on BNTX. Wall Street Zen upgraded BioNTech from a “sell” rating to a “hold” rating in a research note on Saturday, June 7th. The Goldman Sachs Group started coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a “neutral” rating and a $110.00 price objective for the company. Truist Financial reaffirmed a “buy” rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. BMO Capital Markets boosted their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, JPMorgan Chase & Co. dropped their price target on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $137.86.

BioNTech Stock Performance

NASDAQ BNTX opened at $104.80 on Thursday. The firm has a market cap of $25.19 billion, a P/E ratio of -30.82 and a beta of 1.29. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The business’s 50-day moving average price is $102.49 and its 200 day moving average price is $107.40. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC boosted its position in shares of BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company’s stock worth $877,583,000 after buying an additional 1,401,547 shares in the last quarter. Capital International Investors lifted its holdings in BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company’s stock valued at $161,304,000 after purchasing an additional 394,434 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in BioNTech by 94.6% in the 1st quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock valued at $108,859,000 after purchasing an additional 581,173 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company’s stock valued at $63,593,000 after purchasing an additional 694,691 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in BioNTech by 643.7% in the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock valued at $58,747,000 after purchasing an additional 558,389 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.